Related Experiment Video

Updated: Aug 9, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Antiangiogenesis and damaging blood flow by antisense vascular endothelial growth factor oligodeoxynucleotides to

Chunyan Li1, Xiaosong Cheng, Hongchi Jiang

  • 1Laboratory Animal Center, Harbin, China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|April 28, 2006
PubMed

Insights

Antisense VEGF oligodeoxynucleotides (ASODN) formulated in cationic liposomes effectively inhibited lung cancer growth by targeting vascular endothelial growth factor (VEGF). This anti-angiogenesis strategy suppressed tumor progression and damaged tumor blood flow in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Angiogenesis, driven by vascular endothelial growth factor (VEGF), is crucial for lung cancer growth and metastasis.
  • Targeting VEGF offers a potential therapeutic strategy for anti-angiogenesis in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of phosphoro thioate-modified antisense VEGF oligodeoxynucleotides (ASODN) in cationic liposomes for inhibiting Lewis lung carcinoma (LLC) tumor growth.
  • To investigate the anti-angiogenic effects of ASODN targeting VEGF in vitro and in vivo.

Main Methods:

  • ASODN treatment of LLC cells to assess VEGF expression at protein and mRNA levels.
  • In vitro assessment of conditioned media from ASODN-treated LLC cells on bovine aortic endothelial cell proliferation.
  • In vivo evaluation of ASODN therapy on established subcutaneous LLC tumors in mice, analyzing tumor growth, angiogenesis, and blood flow.

Main Results:

  • ASODN significantly downregulated VEGF expression in LLC cells, both in vitro and in vivo.
  • Conditioned media from ASODN-treated cells inhibited endothelial cell proliferation, indicating anti-angiogenic activity.
  • ASODN therapy markedly suppressed LLC tumor growth in mice by inhibiting angiogenesis and impairing tumor vasculature.

Conclusions:

  • ASODN targeting VEGF demonstrates potent anti-cancer activity against lung cancer.
  • This VEGF-targeting ASODN therapy represents a promising strategy for combating lung cancers through anti-angiogenesis.

More Related Videos

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...